Navigation Links
Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
Date:9/23/2008

- 85,000 Expected to Enroll in Phase 4 Study Initiated Pre-Registration -

COLLEGEVILLE, Pa., Sept. 23 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the initiation of the Community Acquired Pneumonia Immunization Trial in Adults a major study in adults of an investigational 13-valent conjugate vaccine designed to help prevent pneumococcal pneumonia -- the leading cause of bacterial pneumonia in adults.

In Europe and the United States, pneumococcal pneumonia is the most common community-acquired bacterial pneumonia, for which the adult mortality rate averages between 10 to 20 percent. That rate may exceed 50 percent in high-risk groups worldwide.

The results from this trial are not intended or required for inclusion in Wyeth's currently planned regulatory filings for the use of the 13-valent pneumococcal conjugate candidate vaccine in adults. Rather, this study is being initiated proactively as part of a Phase 4 commitment, and in agreement with the U.S. Food and Drug Administration (FDA).

The Community Acquired Pneumonia Immunization Trial in Adults is a double-blind, placebo-controlled study expected to enroll approximately 85,000 participants 65 years of age and older. The study is being conducted by the Julius Center for Health Sciences and Primary Care at the University Medical Center Utrecht in the Netherlands. Participants in the trial will receive either Wyeth's investigational 13-valent pneumococcal conjugate vaccine or placebo.

"We are very excited to conduct this major trial addressing the important disease of adult pneumonia," says Marc Bonten, M.D., principal investigator of the trial and Professor of Molecular Epidemiology of Infectious Diseases, D
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
3. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
4. Genzyme Begins Major Expansion of Boston Manufacturing Facility
5. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
6. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
7. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
8. National Surgical Hospitals Acquires Majority Share of Houston-Area Surgery Center
9. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
10. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
11. SPO Medical Announces Major Sales Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, Inc.,("Emerald Dairy" or the "Company") (OTC Bulletin Board: EMDY), a leading,producer and distributor of infant and children,s formul
Breaking Biology Technology:Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Libreville International Conference 2-3 June 2010 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smo
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Increased nicotine levels detected in those who light-up earlier 2The First High Performance Sports Water AquaHydrate to Offer Ionic Minerals Through Exclusive Agreement With Natural Foods Pioneer Trace Minerals 47585 1The First High Performance Sports Water AquaHydrate to Offer Ionic Minerals Through Exclusive Agreement With Natural Foods Pioneer Trace Minerals 47585 2The First High Performance Sports Water AquaHydrate to Offer Ionic Minerals Through Exclusive Agreement With Natural Foods Pioneer Trace Minerals 47585 3JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares 47583 1JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares 47583 2JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares 47583 3CuraGen Updates CR011 vcMMAE Data at ASCO 4512 1CuraGen Updates CR011 vcMMAE Data at ASCO 4512 2CuraGen Updates CR011 vcMMAE Data at ASCO 4512 3CuraGen Updates CR011 vcMMAE Data at ASCO 4512 4CuraGen Updates CR011 vcMMAE Data at ASCO 4512 5CuraGen Updates CR011 vcMMAE Data at ASCO 4512 6CuraGen Updates CR011 vcMMAE Data at ASCO 4512 7
...oduced by a patented microwave process which makes..., even cell attachment, increased cell growth and ...th uunder difficult conditions, including reduced ...ovide a more ecominic alternative to expensive and...
...es are designed for quick and easy protein purific...re two 0.25mm holes laser cut at the conical ends ... incubation of the gel matrix with buffer, during ...the buffer. Following a centrifugation step, the p...
...-art in permanent mounting media. It is designed f...al organic insoluble substrates such as diaminoben... organic solvent compatible chromogen substrates o...y and cytology applications using manual and autom...
...ndustry's first siRNA sequence design software in ...ls consistent with new experimental strategies and... With the introduction of our new, enhanced, and e...to offer the most significant advancement in RNAi ...
Biology Products: